ASX-listed Cynata Therapeutics has signed an MoU with TekCyte Pty Ltd to access its wound dressing technology in the hope of commercialising TekCytes proprietary surface modifications of polymer-coated dressings for the delivery of Cynatas mesenchymal stem cells, or MSC, to wounds.
The Melbourne-based clinical-stage stem cell and regenerative medicine company is specifically looking to use TekCytes technologies in the commercial development of Cynatas MSC product for the treatment of diabetic foot ulcers.
Cynata said its trademarked Cymerus MSCs have already demonstrated promising efficacy in a pre-clinical model of diabetic wounds, often referred to as diabetic ulcers, utilising TekCytes dressing when seeded with MSCs or similar cells.
The company now plans to build on the solid pre-clinical foundation by conducting a clinical trial of its Cymerus MSC product on patients with diabetic foot ulcers using an active dressing supplied by TekCyte.
Cynata expects to start the clinical trial as soon as possible after it completes negotiations with TekCyte on a formal license agreement.
The company says diabetic foot ulcers are a significant medical problem with an estimated market value of nearly US$10 billion based on data sourced from Transparent Market Researchs review of the global diabetic foot ulcers treatment market out to 2027.
In Australia alone, diabetic foot disease results in more than 27,000 hospitalisations, 4,400 amputations and 1,700 deaths annually. Unfortunately, there is also evidence that the burden of this disease is growing year-on-year, and existing treatment options have limited success.
The very encouraging data from the pre-clinical studies at the CTM-CRC with our Cymerus MSC product, especially when compared with other cell products, provides a rational and sound basis for us to proceed with TekCytes patch technology.
Elsewhere in Cynatas labs and clinical trial sites, the company is working to deploy its stem cell technology across a range of ailments, including Osteoarthritis, renal transplantation, idiopathic pulmonary fibrosis and even COVID-19.
Stem cells, most familiar as embryonic stem cells, are special human cells capable of morphing into all other cell varieties from muscles to brain cells.
Whilst stem cell technology has been developing for a decade or two now, it has been routinely based on using hematopoietic stem cells to treat disease. However, a donor can currently transplant these cells only if a perfect match is available.
Instead of the arduous process of undertaking donor match searches, Cynata believes plentiful stem cells can be derived another way. By transforming adult stem cells with a type of genetic reprogramming, the company says it can create pluripotent stem cells that are capable of operating identically to the valuable embryonic cells.
The companys proprietary Cymerus technology uses pluripotent cells combined with a precursor cell called mesenchymoangioblasts, or MCA to fabricate numerous cell therapy products, including mesenchymal stem cells or MSCs.
Importantly, Cynata says it can produce those essential cells at a commercial scale, forgoing the need for multiple donors and conquering the usual supply bottlenecks currently frustrating stem cell therapies and researchers worldwide.
Other candidate diseases facing this potentially boundless technology include asthma, heart attack, sepsis, acute respiratory distress syndrome, or ARDS and cytokine release syndrome.
Plans are already well advanced for further clinical trials of the fascinating Cymerus MSC products in Graft-versus-host Disease, or GvHD through licensee Fujifilm.
GvHD is an all-too-common consequence of traditional stem cell therapies and is one of the earliest ailments to be attacked by Cynatas technology.
Cynata looks to be hurtling down a path to turn science fiction into reality by developing a wound patch that can effectively regenerate the bodys own cells a bit more than just a band-aid approach, perhaps?
Is your ASX-listed company doing something interesting? Contact: matt.birney@wanews.com.au
Follow this link:
Cynata tests wound dressing tech for stem cell therapy delivery - The West Australian
- Fate and long-lasting therapeutic effects of mesenchymal stromal/stem ... - February 6th, 2025
- Nuclear farnesoid X receptor protects against bone loss by driving osteoblast differentiation through stabilizing RUNX2 - Nature.com - January 31st, 2025
- The role of ultrasound combined with water bath in the establishment of animal models of rat urethral stricture - Nature.com - January 25th, 2025
- Why exosome therapy is 2025s It skincare trend - Harpers Bazaar India - January 23rd, 2025
- Identification of glutamine as a potential therapeutic target in dry eye disease - Nature.com - January 23rd, 2025
- Polycystin-1 regulates tendon-derived mesenchymal stem cells fate and matrix organization in heterotopic ossification - Nature.com - January 21st, 2025
- Correction: Adipose-derived mesenchymal stromal cells promote corneal wound healing by accelerating the clearance of neutrophils in cornea -... - January 21st, 2025
- Adipose-Derived Stem Cell Therapy Combined With Platelet-Rich Plasma for the Treatment of Avascular Necrosis of the Talus - Cureus - January 19th, 2025
- Q&A: Mesenchymal stem cells where do they come from and is ... - January 19th, 2025
- An overview of mesenchymal stem cells and their potential ... - January 19th, 2025
- Senescent mesenchymal stem/stromal cells and restoring their cellular ... - January 13th, 2025
- Mesenchymal Stem Cells and Reticulated Platelets: New Horizons in ... - January 13th, 2025
- Mesenchymal Stem Cells/Medicinal Signaling Cells (MSCs) - GlobeNewswire - January 13th, 2025
- A SAGE View of Mesenchymal Stem Cells - PMC - January 13th, 2025
- Mesenchymal stem cell perspective: cell biology to clinical progress - January 3rd, 2025
- Canid alphaherpesvirus 1 infection alters the gene expression and secretome profile of canine adipose-derived mesenchymal stem cells in vitro -... - December 28th, 2024
- MSC-derived exosomal circMYO9B accelerates diabetic wound healing by promoting angiogenesis through the hnRNPU/CBL/KDM1A/VEGFA axis - Nature.com - December 27th, 2024
- Korean researchers prove stem cell therapys effectiveness for hereditary cerebellar ataxia in animal models - KBR - December 25th, 2024
- FDA Approves First MSC Therapy in Steroid-Refractory GVHD - www.oncnursingnews.com/ - December 25th, 2024
- FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid ... - December 22nd, 2024
- FDA Approves Mesenchymal Stromal Cell Therapy for Refractory Acute GVHD in Kids - Medpage Today - December 20th, 2024
- FDA Grants First-Ever Approval for MSC Therapy to Australian Company Mesoblast After Attempting for 4 Years - geneonline - December 20th, 2024
- Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges - Benzinga - December 20th, 2024
- Mesoblast finally pushes GvHD cell therapy over finish line - pharmaphorum - December 20th, 2024
- Mesenchymal stem cells in health and disease - PubMed - December 19th, 2024
- Mesoblast's RYONCIL is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy - The Manila Times - December 19th, 2024
- FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease - PR Newswire - December 19th, 2024
- RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead - MarketWatch - December 17th, 2024
- An injury-induced mesenchymal-epithelial cell niche coordinates regenerative responses in the lung - Science - December 15th, 2024
- New insights into survival of breast cancer cells in the bone marrow - News-Medical.Net - December 9th, 2024
- Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidates (ERNA-101) Ability to Induce and Modulate... - December 7th, 2024
- Enhanced osteogenic potential of iPSC-derived mesenchymal progenitor cells following genome editing of GWAS variants in the RUNX1 gene - Nature.com - December 7th, 2024
- Exploring the potential of MSCs in cancer therapy - News-Medical.Net - December 5th, 2024
- Eterna Therapeutics Partners with MD Anderson to Advance Cancer Cell Therapy Research | ERNA Stock News - StockTitan - December 5th, 2024
- How breast cancer cells survive in bone marrow after remission - Medical Xpress - December 5th, 2024
- A blood glucose fluctuation-responsive delivery system promotes bone regeneration and the repair function of Smpd3-reprogrammed BMSC-derived exosomes... - December 1st, 2024
- Mesenchymal stromal cells alleviate depressive and anxiety-like ... - December 1st, 2024
- Human mesenchymal stem/stromal cell based-therapy in diabetes mellitus ... - December 1st, 2024
- Exploring mesenchymal stem cells homing mechanisms and ... - PubMed - November 26th, 2024
- Macrophage tracking with USPIO imaging and T2 mapping predicts immune rejection of transplanted stem cells - Nature.com - November 26th, 2024
- IL-10RA governor the expression of IDO in the instruction of lymphocyte immunity - Nature.com - November 26th, 2024
- Mesenchymal Stem Cells: Time to Change the Name! - November 26th, 2024
- Researchers have brought the promise of stem cell therapies closer to reality - The Week - November 25th, 2024
- Engineering bone/cartilage organoids: strategy, progress, and application - Nature.com - November 25th, 2024
- Proteomic analysis of human Whartons jelly mesenchymal stem/stromal cells and human amniotic epithelial stem cells: a comparison of therapeutic... - November 20th, 2024
- Clinical outcomes of autologous adipose-derived mesenchymal stem cell combined with high tibial osteotomy for knee osteoarthritis are correlated with... - November 20th, 2024
- Mesenchymal stem cells lineage and their role in disease development - November 18th, 2024
- Mesenchymal Stem Cells - SpringerLink - November 18th, 2024
- Exosomes: The Insulin of Our Era? - University of Miami - November 18th, 2024
- Partner Perspectives: Mesenchymal Stromal Cells Could Serve as Preventive Therapy for Chronic Radiation-Induced Dry Mouth - OncLive - November 10th, 2024
- Skin-care founder Angela Caglia on the stem cell technology that created 437% sales growth: 'It's transformed the business' - Glossy - November 8th, 2024
- Substantial Overview on Mesenchymal Stem Cell Biological and Physical ... - November 8th, 2024
- Regenerative Medical Technology Group Announces the Opening of New Clinic in Dubai on November 23 - Newswire - November 8th, 2024
- BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health - StockTitan - November 8th, 2024
- Stem cell science is dominating the luxury skin-care market as human-derived ingredients become less taboo - Glossy - November 8th, 2024
- BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health - The Manila Times - November 8th, 2024
- SMART researchers develop a method to enhance effectiveness of cartilage repair therapy - MIT News - October 25th, 2024
- Biological functions of mesenchymal stem cells and clinical ... - October 24th, 2024
- Chemical-defined medium supporting the expansion of human mesenchymal ... - October 24th, 2024
- Mesenchymal Stem Cells: Time to Change the Name! - PMC - October 24th, 2024
- Insights into the molecular characteristics of embryonic cranial neural crest cells and their derived mesenchymal cell pools - Nature.com - October 20th, 2024
- Acquisition of durable insulin-producing cells from human adipose tissue-derived mesenchymal stem cells as a foundation for cell- based therapy of... - October 20th, 2024
- Sources and Clinical Applications of Mesenchymal Stem Cells - October 20th, 2024
- Effects of inorganic phosphate on stem cells isolated from human exfoliated deciduous teeth - Nature.com - October 18th, 2024
- Researchers pioneer novel method to enhance effectiveness of MSC therapy for cartilage repair - Medical Xpress - October 18th, 2024
- Healing begins with research: Promising development program on stem cells in rare diseases - Yahoo! Voices - October 15th, 2024
- Unveiling the Immunomodulatory and regenerative potential of iPSC-derived mesenchymal stromal cells and their extracellular vesicles - Nature.com - October 15th, 2024
- Manufactured stem cells could help to treat blood cancers in the future - Health Tech World - October 14th, 2024
- miR-16a-5p antagonizes FGF-2 in ligamentogenic differentiation of MSC: a new therapeutic perspective for tendon regeneration - Nature.com - October 11th, 2024
- Effects, methods and limits of the cryopreservation on mesenchymal stem ... - October 10th, 2024
- ALKBH5 regulates etoposide-induced cellular senescence and osteogenic differentiation in osteoporosis through mediating the m6A modification of VDAC3... - October 10th, 2024
- Mesenchymal stromal cells: Biology of adult mesenchymal stem cells ... - October 8th, 2024
- Clever Robotic clothing and manufactured stem cells to treat cancer among revolutionary healthcare tech projects - University of Strathclyde - October 8th, 2024
- Dr. Peisong Gao, MD, PhD - Hopkins Medicine - October 4th, 2024
- Research to Boost Bone Formation Informs Orthopaedic Treatments - October 4th, 2024
- Garza Laboratory - Johns Hopkins Medicine - October 4th, 2024
- Stem Cell Treatment Promises to Prevent Disease and Slow Aging - Newsweek - September 30th, 2024
- Survival advantage of native and engineered T cells is acquired by mitochondrial transfer from mesenchymal stem cells - Journal of Translational... - September 28th, 2024
- A mathematical insight to control the disease psoriasis using mesenchymal stem cell transplantation with a biologic inhibitor - Nature.com - September 20th, 2024
- Mesenchymal stem cells in tumor microenvironment: drivers of bladder cancer progression through mitochondrial dynamics and energy production -... - September 20th, 2024
Recent Comments